{
    "name": "aminocaproic acid",
    "comment": "Rx",
    "other_names": [
        "Amicar"
    ],
    "classes": [
        "Antifibrinolytic Agents"
    ],
    "source": "https://reference.medscape.com/drug/amicar-aminocaproic-acid-342139",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C",
            "Lactation: Not known whether excreted in breast milk, use caution"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Not known whether excreted in breast milk, use caution"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "In presence of DIC without concomitant heparin",
                "Evidence of active intravascular clotting process"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Use cautioni in renal/cardiac/hepatic impairment",
                "In patients with upper urinary tract bleeding, therapy has been known to cause intrarenal obstruction in form of glomerular capillary thrombosis or clots in renal pelvis and ureters; for this reason, drug should not be used in hematuria of upper urinary tract origin, unless possible benefits outweigh risks",
                "Avoid rapid IV administration",
                "Therapy inhibits both action of plasminogen activators and to a lesser degree, plasmin activity; drug should not be administered without a definite diagnosis and/or laboratory finding indicative of hyperfibrinolysis (hyperplasminemia)",
                "Preservative benzyl alcohol linked to fatal \"Gasping Syndrome\" in premature neonates",
                "Skeletal muscle weakness with necrosis of muscle fibers reported following prolonged administration (rare); Clinical presentation may range from mild myalgias with weakness and fatigue to severe proximal myopathy with rhabdomyolysis, myoglobinuria, and acute renal failure; muscle enzymes, especially creatine phosphokinase (CPK) are elevated; monitor CPK levels in patients on long-term therapy; stop therapy if rise in CPK noted; resolution follows discontinuation of therapy; however, syndrome may recur if therapy restarted",
                "Inhibition of fibrinolysis may theoretically result in clotting or thrombosis; there is no definite evidence that therapy has been responsible for few reported cases of intravascular clotting which followed treatment; rather, it appears that intravascular clotting was most likely due to patient's preexisting clinical condition, eg, the presence of DIC; it has been postulated that extravascular clots formed in vivo may not undergo spontaneous Iysis as do normal clots",
                "Therapy should not be administered with Factor IX Complex concentrates or Anti-Inhibitor Coagulant concentrates, as risk of thrombosis may increase",
                "Reports have appeared in literature of increased incidence of certain neurological deficits,j including hydrocephalus, cerebral ischemia, or cerebral vasospasm associated with use of antifibrinolytic agents in treatment of subarachnoid hemorrhage (SAH); all of these events have also been described as part of the natural course of SAH, or as a consequence of diagnostic procedures such as angiography; drug relatedness remains unclear",
                " "
            ],
            "specific": [
                {
                    "type": "Differentiate primary fibrinolysis from disseminated intravascular coagulation (DIC)",
                    "description": [
                        "When there is uncertainty as to whether cause of bleeding is primary fibrinolysis or disseminated intravascular coagulation (DIC), distinction must be made before administering therapy",
                        "The following tests can be applied to differentiate the two conditions:",
                        "Platelet count is usually decreased in DIC but normal in primary fibrinolysis",
                        "Protamine paracoagulation test is positive in DIC; a precipitate forms when protamine sulfate is dropped into citrated plasma; the test is negative in presence of primary fibrinolysis",
                        "The euglobulin clot Iysis test is abnormal in primary fibrinolysis but normal in DIC "
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "defibrotide",
            "description": {
                "common": "aminocaproic acid decreases effects of defibrotide by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Defibrotide may diminish effects of thrombolytic agents. Consider therapy modification."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethinylestradiol",
            "description": {
                "common": "ethinylestradiol, aminocaproic acid. Other (see comment). Use Caution/Monitor. \nComment: Concomitant use may lead to additive hypercoagulability. Estrogens increase clotting factor production and platelet aggregation; aminocaproic acid inhibits fibrinolysis and activity of plasminogen."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mestranol",
            "description": {
                "common": "mestranol decreases effects of aminocaproic acid by pharmacodynamic antagonism. Use Caution/Monitor. Risk of thromboembolic disorder."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Confusion",
            "percent": null
        },
        {
            "name": "Vision decrease",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Convulsions",
            "percent": null
        },
        {
            "name": "Malaise",
            "percent": null
        },
        {
            "name": "Muscle weakness",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Tinnitus",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Bradycardia",
            "percent": null
        },
        {
            "name": "Thrombosis",
            "percent": null
        },
        {
            "name": "Edema",
            "percent": null
        },
        {
            "name": "Hypotension",
            "percent": null
        },
        {
            "name": "Stroke",
            "percent": null
        },
        {
            "name": "Syncope",
            "percent": null
        },
        {
            "name": "Intracranial hypertension",
            "percent": null
        },
        {
            "name": "Peripheral ischemia",
            "percent": null
        },
        {
            "name": "Pulmonary embolism",
            "percent": null
        },
        {
            "name": "Dyspnea",
            "percent": null
        },
        {
            "name": "Congestion",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Abdominal pain",
            "percent": null
        },
        {
            "name": "Leukopenia",
            "percent": null
        },
        {
            "name": "Agranulocytosis",
            "percent": null
        },
        {
            "name": "Coagulation disorder",
            "percent": null
        },
        {
            "name": "Dry ejaculation",
            "percent": null
        },
        {
            "name": "Injection site reactions",
            "percent": null
        },
        {
            "name": "pain",
            "percent": null
        },
        {
            "name": "necrosis",
            "percent": null
        },
        {
            "name": "Myopathy",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Renal failure",
            "percent": null
        },
        {
            "name": "Anaphylaxis",
            "percent": null
        }
    ]
}